Status:
COMPLETED
The Utility of Concurrent TBS/fNIRS for Antidepressant Treatment Optimization
Lead Sponsor:
Dr Georg Kranz
Collaborating Sponsors:
Chinese University of Hong Kong
Prince of Wales Hospital, Shatin, Hong Kong
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Repetitive transcranial magnetic stimulation (rTMS) with theta bursts (i.e. TBS) of the dorsolateral prefrontal cortex (DLPFC) is an innovative treatment for major depressive disorder (MDD). Indeed, t...
Detailed Description
Please refer to the full proposal
Eligibility Criteria
Inclusion
- MDD group:
- MDD (DSM-5), HAMD17 ≥18, approval for TBS treatment by the physician in charge, stable antidepressive medication 4 weeks before treatment (the sample will include at least 20 drug-naïve patients in order to avoid confounding effects of medication for testing hypothesis 4).
Exclusion
- a history of brain surgery, head injury, stroke or neurodegenerative disorder, diagnosis of personality disorder, psychotic features, active suicidal intent, severe somatic comorbidities, cardiac pacemakers, deep brain stimulation, intracranial metallic particles, history of seizures, antiepileptics and benzodiazepines corresponding to a dose of \>1 mg lorazepam/d, substance dependence or abuse, if it is the primary clinical problem.
- HC group:
- Inclusion Criteria:
- age between 18 and 60, right-handedness.
Key Trial Info
Start Date :
March 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2024
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04526002
Start Date
March 1 2023
End Date
May 15 2024
Last Update
April 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Hong Kong Polytechnic University
Hong Kong, Hong Kong